Insights is the publishing division of the Brainclinics Foundation. Our mission is to make the knowledge, expertise and especially ‘Insights’ gained through our research, widely available through books, PhD theses and interactive media.
To serve the goal of the Brainclinics Foundation, all proceeds are fully invested into Research Institute Brainclinics and Brainclinics Insights, which creates an unprecedented synergy between these divisions and makes it possible to perform research and share new future insights as well.
At the Brainclinics Foundation, it is all about the research and its application!
Within Tabitha Iseger’s doctoral thesis the depression network in the brain is investigated, in order to unravel the pathophysiology underlying depression and gain more insights into the possibilities to optimize and personalize rTMS treatments.
Neurofeedback offers exciting potential for understanding the brain and human behavior. It is helpful as the treatment of epilepsy and ADHD. Its rich history, starting with the discovery of the EEG in 1875, via the beginnings of the field of neurofeedback in 1936, to the foundation of the clinical application in the summer of 1969 is finally brought to life.
It’s a compelling read, often from an eyewitness account, in which we meet an eccentric Wallstreet millionaire and a telepathy-inspired psychiatrist. We read about a Soviet scientists’ encounter with Stalin, get to know a British Baron, a former street gang member and a group of forward thinking West Coast scientists. Discover how they all played a vital role in shaping the future of neuroscience and neurofeedback.
All proceeds from the sale of this beautiful book go toward our research.
With the aim to improve treatment outcome in depressed patients, this book describes the first steps towards the implementation of an EEG biomarker informed protocol. We zoom in on detailed characteristics of biomarkers that proved to be promising. We attempt to utilize automated processes for fast, professionalized EEG assessments. We developed a protocol in which all knowledge on biomarker informed AD prescription was implemented, and performed a feasibility trial. We also compare protocol outcomes with the results of a control group.